Tubulin variants with enhanced electron delocalization
By modifying tubulin proteins with aromatic amino acids to enhance electron delocalization, microtubules achieve quantum coherence at room temperature, addressing the challenge of maintaining quantum phenomena in ambient conditions and enabling practical applications in quantum computing and biosensing.
Patent Information
- Application Number
- PCT/US2026/026818
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Conventional quantum systems require cryogenic conditions to maintain quantum coherence, which is not feasible for practical applications, and natural microtubules lack the structural features to sustain quantum phenomena at ambient temperatures.
Engineer tubulin proteins by incorporating aromatic amino acids to promote pi-pi stacking interactions, forming microtubules that support quantum coherence at room temperature through enhanced electron delocalization.
The engineered microtubules exhibit improved electron delocalization and quantum coherence at ambient conditions, enabling applications in quantum computing, biosensing, and energy transfer systems without the need for cryogenic cooling.
Abstract
Description
Attorney Docket No. 27961-00006 / 1ZED 200007W001TUBULIN VARIANTS WITH ENHANCED ELECTRON DELOCALIZATIONCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application Serial No.63 / 802,052, filed on May 8, 2025, which is incorporated by reference in its entirety.INCORPORATION BY REFERENCE STATEMENT
[0002] This application incorporates by reference a sequence listing submitted herewith as ZedenAI_Tubulin.xml, created on April 22, 2025, and having a file size of 7,383 bytes.BACKGROUND
[0003] The present disclosure relates to synthetic biology, quantum biology, and nanotechnology. It specifically involves the engineering of biological microtubules, formed from modified tubulin proteins, to exhibit quantum coherence properties at room temperature.
[0004] Quantum coherence, i.e. the maintenance of quantum superposition states, is critical for the operation of quantum computing and related technologies. However, conventional quantum systems typically require cryogenic conditions to mitigate thermal noise and decoherence. It would be desirable to provide structures and systems for supporting quantum phenomena such as electron transfer and exciton delocalization.BRIEF DESCRIPTION
[0005] Disclosed in the present disclosure are engineered tubulin proteins and microtubules that can support such quantum phenomena. Biological structures such as natural or wild-type microtubules (cytoskeletal polymers composed of tubulin proteins) do not inherently possess the structural features necessary for sustaining coherence at ambient temperatures. Room -temperature quantum systems may be enabled by engineering tubulin proteins to enhance quantum-relevant properties. By modifying tubulin to promote electron delocalization, microtubules capable of sustaining quantum coherence without the need for extreme environmental conditions can be formed.Attorney Docket No. 27961-00006 / 1ZED 200007W001
[0006] In the present disclosure, natural tubulin proteins can be modified to incorporate aromatic amino acids (e.g., tryptophan, phenylalanine) at strategically selected positions to promote TT-TT (pi-pi) stacking interactions that facilitate electron delocalization.
[0007] Also disclosed are methods for cloning, expressing, and purifying the modified tubulin proteins; protocols for polymerizing these proteins into microtubules; and methods for characterization of the quantum-relevant properties using techniques such as time-resolved fluorescence spectroscopy, cyclic voltammetry, and vibrational spectroscopies (FTIR and Raman). Such quantum-relevant properties may include enhanced fluorescence, conductivity, and electron transfer efficiency.
[0008] These engineered tubulin proteins and microtubules may be applicable in quantum computing, biosensing, and energy transfer systems.
[0009] These and other non-limiting characteristics of the disclosure are more particularly disclosed below.DETAILED DESCRIPTION
[0010] The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0011] As used in the specification and in the claims, the terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named components / ingredients / steps and permit the presence of other components / ingredients / steps. However, such description should be construed as also describing systems or devices or compositions or processes as "consisting of" and "consisting essentially of" the enumerated components / ingredients / steps, which allows the presence of only the named components / ingredients / steps, along with any unavoidable impurities that might result therefrom, and excludes other components / ingredients / steps.
[0012] Numerical values in the specification and claims of this application should be understood to include numerical values which are the same when reduced to the same number of significant figures and numerical values which differ from the stated value byAttorney Docket No. 27961-00006 / 1ZED 200007W001less than the experimental error of conventional measurement technique of the type described in the present application to determine the value.
[0013] All ranges disclosed herein are inclusive of the recited endpoint and independently combinable (for example, the range of “from 2 grams to 10 grams” is inclusive of the endpoints, 2 grams and 10 grams, and all the intermediate values such as 3 grams, 9 grams, 3 grams to 9 grams, etc.).
[0014] A value modified by a term or terms, such as “about” and “substantially,” may not be limited to the precise value specified. The modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression “from about 2 to about 4” also discloses the range “from 2 to 4.” The term “about” may refer to plus or minus 10% of the indicated number.
[0015] The present disclosure refers to aromatic amino acids or residues. “Aromatic” residues refers to phenylalanine (F), histidine (H), tryptophan (W), and tyrosine (Y). All other amino acid residues are non-aromatic residues. “Non-aromatic” residues are alanine (A), cysteine (C), aspartic acid (D), glutamic acid (E), glycine (G), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), pyrrolysine (O), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), selenocysteine (U), and valine (V).
[0016] Acidic and basic residues are determined at pH 7.4. “Acidic” residues refer to C, D, E, and U. “Basic” residues refer to H, K, O, and R.
[0017] “Polar” residues are C, D, E, H, K, N, O, Q, R, S, T and Y. “Non-polar” or “hydrophobic” residues are A, C, F, G, I, L, M, P, V, and W. It is noted that C may be considered both polar and hydrophobic.
[0018] The present disclosure relates to engineered or recombinant tubulin proteins and microtubules formed therefrom. In this regard, tubulin microtubules are a component of the cytoskeleton within the cytoplasm. The microtubules are formed by the polymerization of two proteins, alpha-tubulin and beta-tubulin. A dimer is formed from these two proteins, with the alpha-tubulin subunit facing the minus-end of the microtubule and the beta-tubulin subunit facing the plus-end of the microtubule. The subunits alternate to form a protofilament. Protofilaments in turn assemble around a hollow core to form the microtubule, with the protofilaments running lengthwise along the microtubule wall. In eukaryotes, 13 protofilaments usually associate together to form a microtubule,Attorney Docket No. 27961-00006 / 1ZED 200007W001although other numbers have also been used. In the present disclosure, the alpha-tubulin and beta-tubulin subunits are also referred to individually as having a tertiary structure with a minus-end and a plus-end, oriented in the same direction as the ends of the microtubules.
[0019] Generally, the microtubule has an outer diameter of about 25 nanometers (nm) and an inner diameter of about 15 nm. The microtubule can be described as having an outer surface and an inner surface. Microtubules may have a length ranging from about 1 micrometer to about 50 micrometers.
[0020] In the present disclosure, it is contemplated that enhancing TT-TT stacking through the strategic incorporation of aromatic amino acids into the tubulin proteins might promote electron delocalization, and potentially even quantum coherence, across microtubules. Such quantum effects could be useful for biomolecular electronics and may result in “quantum-enhanced biomaterials.”.
[0021] Some embodiments of the present disclosure thus relate to recombinant tubulin proteins (such as alpha-tubulin or beta-tubulin subunits) that comprise one or more pathways of delocalized electrons extending from a plus-end of the protein to a minusend of the protein. The pathway(s) of delocalized electrons may be formed by pi-pi stacking interactions, such as may arise from the attractive noncovalent interactions between the pi bonds of aromatic rings due to orbital overlap. The pathway(s) of delocalized electrons may be present on either an outer surface or an inner surface of the protein. For purposes of the present disclosure, the outer surface of a given protein corresponds to the surface that would be part of the outer surface of a microtubule. Similarly, the inner surface of a given protein corresponds to the surface that would be part of the inner surface of a microtubule.
[0022] The recombinant tubulin proteins of the present disclosure are enriched in aromatic residues compared to the wild-type of the protein. It is contemplated that generally any source may be used for the tubulin proteins I microtubules. For example, in some particular embodiments, tubulin sequences from Physarum polycephalum (slime mold) are used as the wild-type.
[0023] SEQ ID NO: 1 is the amino acid sequence for a first homolog of the alpha chain of P. polycephalum, labeled as the alpha-1 A chain (UniProt accession number P50258).Attorney Docket No. 27961-00006 / 1ZED 200007W001This wild-type chain contains 12.4% aromatic residues. SEQ ID NO: 2 is the amino acid sequence for a second homolog of the alpha chain of P. polycephalum, labeled as the alpha-1 B chain (UniProt accession number P04105). This wild-type chain contains 12.0% aromatic residues. SEQ ID NO: 3 is the amino acid sequence for a third homolog of the alpha chain of P. polycephalum, labeled as the alpha-2B chain (UniProt accession number P11480). This wild-type chain contains 12.0% aromatic residues. SEQ ID NO: 4 is the amino acid sequence for a first homolog of the beta chain of P. polycephalum, labeled as the beta-1 chain (UniProt accession number P07436). This wild-type chain contains 11.6% aromatic residues. SEQ ID NO: 5 is the amino acid sequence for a second homolog of the beta chain of P. polycephalum, labeled as the beta-2 chain (UniProt accession number P12458). This wild-type chain contains 11.2% aromatic residues.
[0024] In the recombinant proteins of the present disclosure, at least one non-aromatic residue of the wild-type protein is substituted with an aromatic residue to enrich the recombinant tubulin protein (either alpha-tubulin or beta-tubulin). As one non-limiting example, a non-aromatic alanine residue in the protein may be substituted with an aromatic tryptophan residue.
[0025] Thus, in some embodiments, a recombinant alpha-tubulin protein contains at least 57, or at least 58, or at least 59, or at least 60, or at least 62, or at least 64, or at least 66, or at least 68, or at least 70 aromatic residues, including ranges formed from the combination of any of these endpoints. Generally, the alpha-tubulin protein contains at most 90 aromatic residues. Ranges formed from the combination of any of these endpoints are also contemplated as being within the scope of the present disclosure.
[0026] In other embodiments, a recombinant alpha-tubulin protein contains at least 12.5%, or at least 12.6%, or at least 12.8%, or at least 13.0%, or at least 13.2%, or at least 13.4%, or at least 13.6%, or at least 13.8%, or at least 14.0%, or at least 14.2%, or at least 14.4%, or at least 14.6%, or at least 14.8%, or at least 15.0%, or at least 15.2%, or at least 15.4%, or at least 15.6% of aromatic residues. Generally, the alpha-tubulin protein contains at most 20% of aromatic residues. Ranges formed from the combination of any of these endpoints are also contemplated as being within the scope of the present disclosure.Attorney Docket No. 27961-00006 / 1ZED 200007W001
[0027] In some embodiments, a recombinant beta-tubulin protein contains at least 55, or at least 56, or at least 57, or at least 58, or at least 59, or at least 60, or at least 62, or at least 64, or at least 66, or at least 68, or at least 70 aromatic residues. Generally, the beta-tubulin protein contains at most 90 aromatic residues. Ranges formed from the combination of any of these endpoints are also contemplated as being within the scope of the present disclosure.
[0028] In still other embodiments, a recombinant beta-tubulin protein contains at least 11.7%, or at least 11.8%, or at least 12.0%, or at least 12.2%, or at least 12.4%, or at least 12.6%, or at least 12.8%, or at least 13.0%, or at least 13.2%, or at least 13.4%, or at least 13.6%, or at least 13.8%, or at least 14.0%, or at least 14.2%, or at least 14.4%, or at least 14.6%, or at least 14.8%, or at least 15.0%, or at least 15.2%, or at least 15.4%, or at least 15.6% of aromatic residues. Generally, the beta-tubulin protein contains at most 20% of aromatic residues. Ranges formed from the combination of any of these endpoints are also contemplated as being within the scope of the present disclosure.
[0029] In some particular embodiments, a polar non-aromatic residue in the wild-type or control protein is substituted with a polar aromatic residue, i.e. H or Y. In other particular embodiments, a non-polar non-aromatic residue in the wild-type or control protein is substituted with a non-polar aromatic residue, i.e. F or W. In still other particular embodiments, a basic non-aromatic residue in the wild-type or control protein is substituted with a basic aromatic residue, i.e. H. Such substitutions might aid in maintaining the tertiary structure while enhancing electron delocalization.
[0030] The engineered tubulin microtubules of the present disclosure also comprise one or more pathways of delocalized electrons extending from a plus-end of the microtubule to a minus-end of the microtubule. The pathway(s) of delocalized electrons may be formed by pi-pi stacking interactions, and may be present on either an outer surface or an inner surface of the microtubule. It is contemplated that the pathway(s) of delocalized electrons on the microtubule is formed by engineered alpha-tubulin and betatubulin proteins that also have a pathway of delocalized electrons, as described above. The pathway does not have to be a “straight” pathway that extends down one protofilament, and may be formed across protofilaments. Thus, in some embodiments, the tubulin microtubule may also contain wild-type alpha-tubulin and beta-tubulin proteins.Attorney Docket No. 27961-00006 / 1ZED 200007W001
[0031] In other embodiments, the engineered alpha-tubulin and beta-tubulin proteins that have a pathway of delocalized electrons (as described above) make up 10% or more, or 15% or more, or 20% or more, or 25% or more, or 30% or more, or 35% or more, or 40% or more, or 45% or more, or 50% or more, or 55% or more, or 60% or more, or 65% or more, or 70% or more, or 75% or more, or 80% or more, or 85% or more, or 90% or more, or 95% or more of the proteins in the tubulin microtubule, including ranges formed from the combination of any of these endpoints.
[0032] A recombinant tubulin protein may generally be made by replacing at least one non-aromatic residue of a wild-type tubulin protein sequence with an aromatic residue to obtain a recombinant tubulin protein sequence. The recombinant tubulin protein sequence is then inserted into an expression vector, which is inserted into a host cell to express the recombinant tubulin protein. The expressed protein is then purified.
[0033] It is contemplated that recombinant modified tubulin proteins engineered with site-specific aromatic substitutions will exhibit enhanced electron delocalization and measurable coherence-like signatures (e.g., altered fluorescence lifetimes, improved electron transport, distinct vibrational modes) compared to wild-type tubulin proteins. These effects may be sensitive to environmental factors (e.g., temperature, magnetic fields) and isotopic substitution.
[0034] Initially, a wild-type tubulin sequence, for example from Physarum polycephalum, is modified to replace specific non-aromatic residues with aromatic residues. This may be done, for example, via site-directed mutagenesis. Wild-type tubulin can be obtained from commercial sources (e.g., Cytoskeleton Inc.), and can serve as a baseline for measuring improved properties too.
[0035] It is contemplated that structural analysis may be done to identify dimer interfaces and regions conducive to TT-TT interactions. This may be done, for example using PDB data and AlphaFold2 predictions. Advanced molecular dynamics simulations and density functional theory (DFT) analyses may be employed to predict conformational changes and the impact on electron distribution and transport properties following mutation. High-performance computing may be done to simulate the dynamics of candidate mutants to optimize the likelihood that global folding and microtubule polymerization remain intact. Hybrid quantum mechanics / molecular mechanics methodsAttorney Docket No. 27961-00006 / 1ZED 200007W001may be applied to predict changes in electron density and estimate delocalization parameters. Tools like Rosetta may be used to assess folding stability. The effect of isotopic substitutions (e.g., deuteration, 13C labeling) may be simulated to predict any influence on vibrational and electron coherence properties. This minimizes the risk of selecting mutations that might disrupt protein folding or polymerization, and can guide the selection of the most promising mutations while minimizing costly experimental iterations.
[0036] The modified tubulin sequences / genes may then be inserted into an expression vector, which is inserted into a host cell to express the recombinant tubulin protein. For example, the pET series of expression vectors may be used for prokaryotic expression, or the pYES2 series of expression vectors may be used for yeast expression. In various embodiments, the host cell may be a bacterium, a yeast, an insect cell, a plant cell, or a mammalian cell. Examples of such host cells may include Escherichia coli, Pichia pastoris, and / or Saccharomyces cerevisiae. For example, E. coli may be used for rapid screening of constructs for initial folding, using minimal post-translational modifications. Yeast such as Pichia pastoris may be used for parallel expression to capture eukaryotic folding and modifications.
[0037] Quality control may be performed using various assays. Biophysical assays such as SDS-PAGE, circular dichroism (CD) spectroscopy, and / or dynamic light scattering (DLS) may be used to verify proper folding. Negative-stain electron microscopy (EM) and / or atomic force microscopy (AFM) could be used to confirm the formation of microtubule-like structures.
[0038] Redundancy may be obtained by running parallel expression systems (e.g. E. coli and yeast) and including multiple control constructs to quickly rule out artifacts. Several different controls could be used. Wild-type tubulin can be used as a control. Mutant controls may also be useful. This may include, for example, non-aromatic (scrambled-sequence) tubulin variants or isotopically labeled variants (e.g. deuterated or13C-enriched) to assess the impact of mass and vibrational changes on coherence.
[0039] Purification of the expressed proteins may be done using any suitable method. For example, affinity chromatography (e.g., His-tag / Ni-NTA systems), followed by sizeexclusion chromatography, could be performed to achieve high purity and homogeneity.Attorney Docket No. 27961-00006 / 1ZED 200007W001The recombinant tubulin sequences may include any tags that may be useful for purification.
[0040] Next, engineered tubulin proteins may be polymerized in vitro using established protocols that include the addition of GTP and optimized ionic buffers at 37°C, to form microtubules that desirably have enhanced electron delocalization. The formation of microtubules can be confirmed via high-resolution imaging techniques such as fluorescence microscopy, electron microscopy such as cryogenic electron microscopy (cryo-EM), or atomic force microscopy (AFM).
[0041] The recombinant microtubules, containing the engineered tubulin proteins described above, may then be tested for quantum-relevant properties. This may be done, for example, using fluorescence spectroscopy, cyclic voltammetry, impedance spectroscopy, and / or vibrational spectroscopy.
[0042] Enhanced fluorescence emission (typically in the 350-450 nm range), as indicated by increased intensity or spectral shifts, may indicate improved electron delocalization. Time-resolved fluorescence spectroscopy can be utilized to quantify these enhancements. Emission spectra may be measured under UV-vis excitation. Ultrafast pump-probe and time-resolved THz spectroscopy could be used to capture delocalization lifetimes. These methods may be sensitive to coherent excitonic states beyond conventional fluorescence.
[0043] Electrochemical techniques such as cyclic voltammetry and impedance spectroscopy may be used to measure improvements in electron transfer efficiency along the engineered microtubules. For example, microtubule networks could be immobilized on electrodes (perhaps functionalized with tau proteins or poly-L-lysine for enhanced adhesion) to assess electron transfer efficiency. Using cyclic voltammetry, improved properties could manifest as enhanced current response (higher peak current) or lower overpotentials. This would indicate more efficient electron flow. In impedance spectroscopy, a reduced impedance would suggest the presence of more efficient pathways for electron transport.
[0044] Conductive AFM could be used to resolve spatial variations in electron flow along the polymer. Magnetic Field Modulation could be used to introduce controlledAttorney Docket No. 27961-00006 / 1ZED 200007W001magnetic fields during measurements, which would permit the evaluation of sensitivity of electron transport to spin coherence effects.
[0045] Vibrational spectroscopy (e.g. FTIR and Raman) could be used to monitor specific vibrational modes (e.g., C=C stretching) that confirm the presence of extended conjugated systems resulting from aromatic residue incorporation. Resonance Raman spectroscopy could be used amplify signals associated with delocalized electrons.
[0046] Computational correlation could also be used to compare observed vibrational shifts with DFT predictions to validate the enhanced conjugation and electron density redistribution. Global fitting and spectral deconvolution could be used to distinguish quantum-coherent signals from classical fluorescence.
[0047] High-resolution structural characterization of the microtubules could be performed, for example by using cryo-EM analysis or Small-Angle X-ray Scattering (SAXS). This could be done to validate polymer integrity and / or document the structural changes resulting from specific aromatic substitutions. High-resolution AFM could be used under both ambient and cryogenic conditions to assess surface morphology and local structural deviations.
[0048] Experiments to assess the effect of the environment could be performed. Fluorescence, electron transfer, and vibrational spectra could be measured at varying temperatures to test the robustness of the coherence signatures. Comparison against deuterated and13C-enriched tubulin variants could determine whether changes in mass and vibrational dynamics affect coherence. External magnetic fields could be applied to test for field-dependent decoherence effects.
[0049] In other embodiments, it is contemplated that the tubulin proteins could be modified to include metal-ion coordination sites. These are sites to which a metal ion may bind during complexation. In particular embodiments, the tubulin protein is modified to place amino acid residues with lone electron pairs in specific locations to form one or more metal-ion coordination sites. Amino acids that contain lone electron pairs, for example due to the presence of an oxygen or nitrogen atom, and which could serve as a metal ligand include cysteine (C), aspartic acid (D), glutamic acid (E), histidine (H), lysine (K), methionine (M), asparagine (N), pyrrolysine (O), glutamine (Q), arginine (R), serine (S), threonine (T), selenocysteine (U), and tyrosine (Y).Attorney Docket No. 27961-00006 / 1ZED 200007W001
[0050] In the present disclosure, the recombinant tubulin protein (either alpha-tubulin or beta-tubulin) and the resulting microtubule may be enriched in these amino acids with lone electron pairs compared to a wild-type of the protein. Thus, in some embodiments, a recombinant alpha-tubulin protein contains at least 265 of these amino acid residues. In other embodiments, a recombinant alpha-tubulin protein contains at least 58.8% of these residues. Generally, the alpha-tubulin protein contains at most 70% of these residues. In some embodiments, a recombinant beta-tubulin protein contains at least 291 of these amino acid residues. In other embodiments, a recombinant beta-tubulin protein contains at least 62.2% of these residues. Generally, the beta-tubulin protein contains at most 70% of these residues.
[0051] The modified tubulin proteins and microtubules can be used in various applications. Those may include quantum computing, where the engineered microtubules could serve as biologically based qubits or quantum interconnects in scalable quantum networks. The quantum-enhanced properties of the microtubules could enable the development of highly sensitive biosensors for detecting chemical or biological analytes. These microtubules could be integrated into devices as part of energy transfer systems for efficient light-harvesting or charge-separation processes.
[0052] The microtubules may enable sustained quantum coherence at ambient conditions (i.e. room temperature), eliminating the need for cryogenic cooling. Here, “room temperature” may refer to a temperature range of 20°C to 25°C. Strategic incorporation of aromatic amino acids fosters robust pi-pi interactions, significantly improving electron transfer efficiency. The engineered microtubules offer versatile applications in quantum computing, biosensing, and energy conversion systems.
[0053] The present disclosure has been described with reference to exemplary embodiments. Modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims
Attorney Docket No. 27961-00006 / 1ZED 200007W001CLAIMS:
1. A recombinant tubulin protein, comprising a pathway of delocalized electrons extending from a plus-end of the protein to a minus-end of the protein.
2. The protein of claim 1, wherein the pathway of delocalized electrons is formed by TT-TT stacking interactions.
3. The protein of claim 1, wherein the pathway of delocalized electrons is present on an outer surface of the protein.
4. The protein of claim 1, wherein the pathway of delocalized electrons is present on an inner surface of the protein.
5. The protein of claim 1, wherein the recombinant protein is enriched in aromatic residues compared to a wild-type of the protein.
6. A recombinant alpha-tubulin protein that contains at least 57, or at least 58, or at least 59, or at least 60, or at least 62, or at least 64, or at least 66, or at least 68, or at least 70 aromatic residues.
7. A recombinant alpha-tubulin protein that contains at least 12.5%, or at least 12.6%, or at least 12.8%, or at least 13.0%, or at least 13.2%, or at least 13.4%, or at least 13.6%, or at least 13.8%, or at least 14.0%, or at least 14.2%, or at least 14.4%, or at least 14.6%, or at least 14.8%, or at least 15.0%, or at least 15.2%, or at least 15.4%, or at least 15.6% of aromatic residues.
8. A recombinant beta-tubulin protein that contains at least 55, or at least 56, or at least 57, or at least 58, or at least 59, or at least 60, or at least 62, or at least 64, or at least 66, or at least 68, or at least 70 aromatic residues.
9. A recombinant beta-tubulin protein that contains at least 11.7%, or at least 11.8%, or at least 12.0%, or at least 12.2%, or at least 12.4%, or at least 12.6%, or at least 12.8%, or at least 13.0%, or at least 13.2%, or at least 13.4%, or at least 13.6%, or at least 13.8%, or at least 14.0%, or at least 14.2%, or at least 14.4%, or at least 14.6%,Attorney Docket No. 27961-00006 / 1ZED 200007W001or at least 14.8%, or at least 15.0%, or at least 15.2%, or at least 15.4%, or at least 15.6% of aromatic residues.
10. A microtubule, comprising a pathway of delocalized electrons extending from a plus-end of the microtubule to a minus-end of the microtubule.
11. The microtubule of claim 10, wherein the pathway of delocalized electrons is formed by TT-TT stacking interactions.
12. The microtubule of claim 10, wherein the pathway of delocalized electrons is present on an outer surface of the protein.
13. The microtubule of claim 10, wherein the pathway of delocalized electrons is present on an inner surface of the protein.
14. The microtubule of claim 10, wherein the microtubule is enriched in aromatic residues compared to a wild-type of the microtubule.
15. The microtubule of claim 10, wherein the microtubule is formed from alphatubulin proteins and beta-tubulin proteins.
16. The microtubule of claim 15, wherein at least one alpha-tubulin protein contains at least 57, or at least 58, or at least 59, or at least 60, or at least 62, or at least 64, or at least 66, or at least 68, or at least 70 aromatic residues.
17. The microtubule of claim 15, wherein at least one alpha-tubulin protein contains at least 12.5%, or at least 12.6%, or at least 12.8%, or at least 13.0%, or at least 13.2%, or at least 13.4%, or at least 13.6%, or at least 13.8%, or at least 14.0%, or at least 14.2%, or at least 14.4%, or at least 14.6%, or at least 14.8%, or at least 15.0%, or at least 15.2%, or at least 15.4%, or at least 15.6% of aromatic residues.
18. The microtubule of claim 15, wherein at least one beta-tubulin protein contains at least 55, or at least 56, or at least 57, or at least 58, or at least 59, or at least 60, or at least 62, or at least 64, or at least 66, or at least 68, or at least 70 aromatic residues.Attorney Docket No. 27961-00006 / 1ZED 200007W00119. The microtubule of claim 15, wherein at least one beta-tubulin protein contains at least 11.7%, or at least 11.8%, or at least 12.0%, or at least 12.2%, or at least 12.4%, or at least 12.6%, or at least 12.8%, or at least 13.0%, or at least 13.2%, or at least 13.4%, or at least 13.6%, or at least 13.8%, or at least 14.0%, or at least 14.2%, or at least 14.4%, or at least 14.6%, or at least 14.8%, or at least 15.0%, or at least 15.2%, or at least 15.4%, or at least 15.6% of aromatic residues.
20. A method of making a recombinant tubulin protein, comprising:replacing at least one non-aromatic residue of a wild-type tubulin protein sequence with an aromatic residue to obtain a recombinant tubulin protein sequence;inserting the recombinant tubulin protein sequence into an expression vector;inserting the expression vector into a host cell to express the recombinant tubulin protein; andpurifying the expressed protein.
21. The method of claim 20, wherein the host cell is a bacterium, a yeast, an insect cell, a plant cell, or a mammalian cell.
22. A method of making a microtubule, comprising:polymerizing alpha-tubulin proteins and beta-tubulin proteins to make the microtubule;wherein the microtubule comprises a pathway of delocalized electrons extending from a plus-end of the microtubule to a minus-end of the microtubule.
23. The method of claim 22, further comprising confirming microtubule formation using imaging.
24. The method of claim 23, wherein the imaging comprises fluorescence microscopy, electron microscopy, or atomic force microscopy.
25. A method of testing a recombinant microtubule, comprising:testing the recombinant microtubule using fluorescence microscopy, cyclic voltammetry, impedance spectroscopy, and / or vibrational spectroscopy; andAttorney Docket No. 27961-00006 / 1ZED 200007W001comparing the test results to test results for a wild-type microtubule to determine whether the recombinant microtubule has improved electron delocalization.
26. A method of using a microtubule for quantum computing, comprising using the microtubule as a qubit or interconnect in a quantum network.
27. A method of using a microtubule as a biosensor, comprising exposing the microtube to a chemical or biological analyte.
28. A method of using a microtubule for energy transfer, comprising integrating the microtubule into a device.
29. The method of claim 28, wherein the device harvests light or separates charges.
